Real-world Experience in Managing Atrial Fibrillation in Patients with Renal Impairment; Rivaroxaban versus Warfarin.

Background: The use of rivaroxaban in patients with atrial fibrillation (AF) and chronic kidney disease (CKD) poses the risk of over- or underdosing. We aimed to compare rivaroxaban and warfarin in AF patients with moderate and severe renal impairment.

Methods: This retrospective study was conducted between 2015 and 2016 to compare the use of warfarin ( = 164) and rivaroxaban ( = 149) in patients with AF and moderate or severe CKD.